Eric Weinhandl

@ericweinhandl.bsky.social

Kidney epidemiology (PhD) + biostatistics (MS). My primary interest is home dialysis. Christian in the LCMS, lifelong Minnesotan, Ole, Gopher, husband, dad x4.

In talks and in our online course thebullshitmachines.com, I worry about how the extremely high cost of training LLMs concentrates power in the hands of the very few to shape our information environment. Grok going off the rails with talk of White Genocide is a striking example.

Elon Musk’s Grok AI Can’t Stop Talking About ‘White Genocide’

In response to X user queries about everything from sports to Medicaid cuts, the xAI chatbot inserted unrelated information about “white genocide” in South Africa.

wired.com

I would like to thank Maarten Naesens, MD for the opportunity to write my position statement on where the field of transplantation needs to shift to. Now is the time to improve quality and participation of life after transplant. bit.ly/4jQToAP #openaccess

Frontiers Publishing Partnerships | Life After Kidney Transplantation: The Time for a New Narrative

The first successful kidney transplant in December 1954 between the Herrick brothers ushered in a new field of medicine. Over the almost seventy years, tho...

bit.ly

I made the same point in a KI Reports paper a few years ago: erythropoietin resistance index (ERI) looks like a novel metric, but really, it provides no better risk discrimination than ESA dose itself. Big ESA dose = higher risk of MACE. journals.lww.com/kidney360/ab...

Association of Different Definitions of... : Kidney360

thods: ASCEND-D (NCT02879305), a large event-driven cardiovascular outcomes trial, randomized 2,964 patients receiving maintenance dialysis to either daprodustat or conventional ESAs. All patients r...

journals.lww.com

You don’t want to miss this. Apply for a Home Dialysis University Scholarship: 📍 Chicago: Sept 14–16 💻 Virtual series through June 2026 🧠 Expert-led, case-based learning 🤝 Connect with peers + mentors ✅ For 2nd or 3rd year nephrology fellows 🔗 bit.ly/ASNhdu

Bild

🚨New Study in Annals🚨 GLP1ra & SGLT2i are the only diabetes meds that reduce heart attacks & death But can't work if can't prescribe TLDR 40% Medicaid enrollees have restricted access to GLP1 & 25% to SGLT2i much state/plan variability GLP access plateaued in '22 bit.ly/3Y72K2z

Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program | Annals of Internal Medicine

Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease an...

acpjournals.org